Polar Bear Genome BioPharma

Polar Bear Genome BioPharma is a South Korean biotechnology company that utilizes comparative genomics to develop treatments for metabolic and intractable diseases. The company's core strategy involves analyzing the genome of polar bears to identify genetic factors that prevent metabolic syndrome despite a high-fat diet and sedentary periods during hibernation. Their research focuses on translating these evolutionary adaptations into human therapeutics for obesity, non-alcoholic steatohepatitis (NASH), and chronic kidney disease. Currently in the pre-clinical stage, the company aims to provide first-in-class treatments by leveraging unique biological insights from extremophile species.